Portal de Periódicos da CAPES

Granisetron reduces the incidence and severity of nausea and vomiting after laparoscopic cholecystectomy

1997; Springer Science+Business Media; Volume: 44; Issue: 4 Linguagem: Inglês

10.1007/bf03014460

1496-8975

Yoshitaka Fujii, Hiroyoshi Tanaka, Hidenori Toyooka,

Pathogenesis and Treatment of Hiccups

Postoperative nausea and vomiting (PONV) are commonly observed undesirable consequences of laparoscopic cholecystectomy. This study was undertaken to compare granisetron, a selective 5-hydroxytryptamine type 3 receptor antagonist, with dropendol for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy. Eighty patients, aged 25–65 yr. scheduled for elective laparoscopic cholecystectomy were enrolled in a randomized, double-blinded investigation and assigned to one of three treatment regimens: placebo (saline), 1.25 mg dropendol (approximately 25μg·kg−1) or 3 mg granisetron (approximately 60μg·kg−1). The study drugs were administerediv immediately before the induction of anaesthesia. A standard general anaesthetic technique was employed throughout. Nausea, vomiting and safety assessments were performed continuously dunng the first 24 hr after anaesthesia. The incidence of PONV was 46% with placebo, 41 % with dropendol and 15% with granisetron (P< 0.05; overall C2 test). Four patients who had received placebo and two who had received dropendol required another rescue antiemetic, compared with none who had received granisetron (P< 0.05). Adverse events postoperatively were not different among the groups. Granisetron is more effective than dropendol and placebo for reducing the incidence and seventy of PONV after laparoscopic cholecystectomy.